Myomo (MYO) EBITDA Margin (2016 - 2025)
Myomo's (MYO) quarterly EBITDA Margin came in at 34.86% in Q3 2025, down 2446.0% on a YoY basis from 1.49% in Q3 2024, and up 26.7% quarter-over-quarter from 47.56% in Q2 2025.
Powered by 
Analysis
Myomo (MYO) EBITDA Margin (2016 - 2025) Analysis & Trends
Myomo (MYO) has reported EBITDA Margin for 10 consecutive years, with 34.86% the latest figure, recorded in Q3 2025.
- For the quarter ending Q3 2025, EBITDA Margin fell 2446.0% year-over-year to 34.86%; the trailing twelve-month figure through Sep 2025 stood at 28.51% (up 475.0% YoY), and the FY2024 full-year result was 19.07%, up 2371.0% from the prior year.
- EBITDA Margin improved to 34.86% in Q3 2025 per MYO's latest filing, from 47.56% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2.03% in Q4 2024 and bottomed at 125.51% in Q1 2021.
- Historically, EBITDA Margin has averaged 54.45% across 5 years, with a median of 51.16% in 2023.
- The sharpest annual moves came in 2021 and 2025: EBITDA Margin soared 24803 bps in 2021, then slumped 3273 bps in 2025.
- Over 5 years, EBITDA Margin stood at 67.11% in 2021, then grew by 18 bps to 55.16% in 2022, then increased by 7 bps to 51.16% in 2023, then surged by 96 bps to 2.03% in 2024, then slumped by 1615 bps to 34.86% in 2025.
- According to Business Quant data, EBITDA Margin over the past three periods registered 34.86%, 47.56%, and 35.8% for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.91 Bn | 175.30 Bn | 7.27 Bn | 13.44% |
| 2 | Intuitive Surgical | 127.79 Bn | 122.57 Bn | 1.96 Bn | 33.60% |
| 3 | Medtronic | 116.85 Bn | 108.03 Bn | 6.34 Bn | 18.08% |
| 4 | Stryker | 104.37 Bn | 100.89 Bn | 4.50 Bn | 25.18% |
| 5 | Boston Scientific | 63.81 Bn | 63.27 Bn | 3.85 Bn | 21.65% |
| 6 | Edwards Lifesciences | 49.92 Bn | 45.66 Bn | 1.35 Bn | 29.48% |
| 7 | Alcon | 33.04 Bn | 31.59 Bn | 1.68 Bn | 0.40% |
| 8 | Dexcom | 32.19 Bn | 30.25 Bn | 830.00 Mn | 24.33% |
| 9 | Steris | 20.67 Bn | 20.18 Bn | 684.20 Mn | 19.15% |
| 10 | Myomo | 56.29 Mn | 37.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -34.86% |
| Jun 30, 2025 | -47.56% |
| Mar 31, 2025 | -35.80% |
| Dec 31, 2024 | -2.03% |
| Sep 30, 2024 | -10.40% |
| Jun 30, 2024 | -14.83% |
| Mar 31, 2024 | -103.58% |
| Dec 31, 2023 | -51.16% |
| Sep 30, 2023 | -39.85% |
| Jun 30, 2023 | -18.51% |
| Mar 31, 2023 | -77.49% |
| Dec 31, 2022 | -55.16% |
| Sep 30, 2022 | -71.03% |
| Jun 30, 2022 | -78.74% |
| Mar 31, 2022 | -70.81% |
| Dec 31, 2021 | -67.11% |
| Sep 30, 2021 | -46.31% |
| Jun 30, 2021 | -83.74% |
| Mar 31, 2021 | -125.51% |
| Dec 31, 2020 | -44.50% |